Skip to main content
. 2022 Mar 11;6(6):1629–1636. doi: 10.1182/bloodadvances.2020003698

Figure 3.

Figure 3.

Biomarker analysis. (A) Overall response by DLBCL subtype. (B) Overall response by CD79B and MYD88 mutation status. ORR between the CD79B ITAM mutant and nonmutant groups (P = .462), MYD88L265P mutant and nonmutant groups (P = .714), and CD79B ITAM and MYD88L265P double-mutant and others group (P = .641). The P values were calculated using Fisher’s exact test.